2025年中国创新药BD交易激增,PD-1/VEGF双抗与TCE赛道或成下一站焦点“不少基金团队都在研究下一个BD趋势,并且根据预测进行加仓。”一名投资人说到。前一阵子,恒瑞和GSK的BD交易从涉及药物数量和总付款规模上,都刷新了中国创新药单笔交易的新纪录。2025年上半年,中国创新药BD交易金额已超过484亿美元,其中总首付款超过20亿美元。在众多案例的积攒下,不少产业人士试图总结规律,希望能把...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.